Biotech & Pharma · Week of Nov 2, 2026
Q3 earnings, FDA filings and GLP-1 deals: the week in biotech
Third-quarter earnings dominated the week, alongside new regulatory filings, late-stage data and GLP-1 activity from Lilly and AbbVie's Allergan Aesthetics.
Third-quarter results made up most of the week's releases. Precigen reported net income of $35.8 million on PAPZIMEOS sales, and Vera Therapeutics booked its first product revenue, $10.3 million from TRUTAKNA. Perrigo cut its full-year outlook and agreed to sell its Infant Formula business. Seres Therapeutics and IDEAYA Biosciences reported losses and set out pipeline plans. Several companies also reported regulatory steps. Vera filed an sBLA for full approval of TRUTAKNA, IDEAYA completed an NDA submission for darovasertib plus crizotinib, and Seres plans to submit a SER-155 study design to the FDA in the first quarter of 2027.
GLP-1 medicines were a second thread. Eli Lilly agreed with Hims & Hers to offer Zepbound and Foundayo at Lilly's self-pay prices on the telehealth platform. AbbVie's Allergan Aesthetics presented Phase 4 data on aesthetic treatment in patients taking GLP-1 medications. In late-stage clinical data, Johnson & Johnson said its oral peptide ICOTYDE met the primary endpoint in a Phase 3 psoriatic arthritis study.
Perrigo Company plc
Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations
Perrigo reported third-quarter All In net sales down 5.2% to $989 million and a diluted loss per share of $(0.10), and lowered its Core adjusted EPS outlook to $2.15 to $2.35 from $2.25 to $2.55. After quarter-end it agreed to divest its Infant Formula business for up to $175 million, including $40 million upfront and up to $135 million tied to net sales milestones through 2030.
AbbVie
Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
Allergan Aesthetics, an AbbVie company, presented two Phase 4 studies at ASDS 2026 in adults on GLP-1 medications, reporting mean FACE-Q satisfaction improvements of 42.4 points in HARMONY IN DIVERSITY Cohort 2 and 39.6 points in an interim HALO analysis. The company says most treatment-related adverse events were mild and nonserious, and HARMONY IN DIVERSITY showed no evidence of distant spread of toxin.
Eli Lilly and Company
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
Eli Lilly and Hims & Hers announced on Nov. 6, 2026 that eligible patients prescribed Zepbound or Foundayo on the Hims & Hers platform can obtain them at Lilly's self-pay prices, starting at $149 per month for Foundayo and $299 per month for Zepbound. As part of the deal, Hims & Hers committed not to offer compounded copies of Lilly's GLP-1s, which it says it has never offered.
Precigen, Inc.
Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
Precigen reported third-quarter total revenues of $74.1 million and net income of $35.8 million, with PAPZIMEOS net product revenue up 37% quarter-over-quarter to $72.9 million. The company says operating cash flow of $11.9 million reached positive territory a quarter ahead of guidance, and the FDA granted Platform Technology Designation to its AdenoVerse platform in September 2026.
Johnson & Johnson
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Johnson & Johnson said once-daily oral ICOTYDE (icotrokinra) met the primary endpoint in the Phase 3 ICONIC-PsA 1 study, with 58% of biologic-naive psoriatic arthritis patients achieving ACR20 at Week 16 versus 41% on placebo. The drug is approved in the U.S. for moderate-to-severe plaque psoriasis but not for psoriatic arthritis, and the company reports no new safety signals through Week 24.
Seres Therapeutics, Inc.
SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)
Seres Therapeutics reported a third-quarter net loss of $16.3 million and had $17.5 million in cash as of September 30, 2026, plus a $12.5 million payment from Nestlé in October; it expects to fund operations through the first quarter of 2027. The company plans a funding-dependent study of SER-155 to prevent immune checkpoint inhibitor-related enterocolitis and expects to submit the design to the FDA in the first quarter of 2027.
Vera Therapeutics, Inc.
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Vera Therapeutics reported its first product revenue, $10.3 million from TRUTAKNA, and a net loss of $93.7 million, and submitted an sBLA on November 3, 2026 for full approval in adults with primary IgAN, with a decision expected in mid-2027. The filing is based on ORIGIN 3 data showing an annualized eGFR slope of -0.6 versus -5.6 mL/min/1.73m²/year for placebo through 104 weeks.
IDEAYA Biosciences, Inc.
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
IDEAYA Biosciences reported a third-quarter net loss of $125.7 million and said it completed an NDA submission for darovasertib plus crizotinib in metastatic uveal melanoma under the Real-Time Oncology Review program. The company is closing its Phase 3 OptimUM-010 trial over enrollment challenges, with estimated savings of $100-125 million, and plans two Phase 3 trials of IDE849 by year end, with cash runway guidance into 2030.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not ZenFlex Wire reporting.